JP2018534306A - 創傷治癒のためのプラスミノーゲン投与計画 - Google Patents

創傷治癒のためのプラスミノーゲン投与計画 Download PDF

Info

Publication number
JP2018534306A
JP2018534306A JP2018524824A JP2018524824A JP2018534306A JP 2018534306 A JP2018534306 A JP 2018534306A JP 2018524824 A JP2018524824 A JP 2018524824A JP 2018524824 A JP2018524824 A JP 2018524824A JP 2018534306 A JP2018534306 A JP 2018534306A
Authority
JP
Japan
Prior art keywords
wound
medicament
plasminogen
dose
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018524824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534306A5 (cg-RX-API-DMAC7.html
Inventor
ウルフ・ベルトヘイム
トール・ニー
ピエール・ローラン
マルタン・ロビタイユ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biotherapeutics Ltd
Original Assignee
Prometic Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Ltd filed Critical Prometic Biotherapeutics Ltd
Publication of JP2018534306A publication Critical patent/JP2018534306A/ja
Publication of JP2018534306A5 publication Critical patent/JP2018534306A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2018524824A 2015-11-10 2016-11-10 創傷治癒のためのプラスミノーゲン投与計画 Pending JP2018534306A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562253352P 2015-11-10 2015-11-10
US62/253,352 2015-11-10
PCT/IB2016/001606 WO2017081529A1 (en) 2015-11-10 2016-11-10 Plasminogen dosage regimen for wound healing

Publications (2)

Publication Number Publication Date
JP2018534306A true JP2018534306A (ja) 2018-11-22
JP2018534306A5 JP2018534306A5 (cg-RX-API-DMAC7.html) 2019-12-19

Family

ID=57485826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018524824A Pending JP2018534306A (ja) 2015-11-10 2016-11-10 創傷治癒のためのプラスミノーゲン投与計画

Country Status (14)

Country Link
US (1) US20180326023A1 (cg-RX-API-DMAC7.html)
EP (1) EP3373957A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018534306A (cg-RX-API-DMAC7.html)
KR (1) KR20180070708A (cg-RX-API-DMAC7.html)
CN (1) CN108289934A (cg-RX-API-DMAC7.html)
AU (1) AU2016352183A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018009476A8 (cg-RX-API-DMAC7.html)
CA (1) CA3004509A1 (cg-RX-API-DMAC7.html)
IL (1) IL259172A (cg-RX-API-DMAC7.html)
MX (1) MX2018005876A (cg-RX-API-DMAC7.html)
RU (1) RU2018121234A (cg-RX-API-DMAC7.html)
TW (1) TW201722464A (cg-RX-API-DMAC7.html)
WO (1) WO2017081529A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201803010B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN111432762B (zh) * 2017-12-15 2023-01-13 墨尼克医疗用品有限公司 预防性敷料
BR112020003022A2 (pt) 2017-12-26 2020-08-25 Hirotaro Fukuoka composição farmacêutica para o uso no crescimento de cabelo, modificação do couro cabeludo ou pele, cicatrização de uma ferida, promoção da osteogênese ou modificação do cabelo
JP7682567B2 (ja) * 2020-11-17 2025-05-26 泰▲倫▼基国▲際▼有限公司 Ngfレベルを増加させる方法及び薬剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020297A2 (en) * 2001-09-06 2003-03-13 Omnio Ab Method of improving wound healing
WO2009093970A1 (en) * 2008-01-22 2009-07-30 Omnio Healer Ab Method of improving wound healing
JP2018505209A (ja) * 2014-12-19 2018-02-22 プロメティック・バイオセラピューティクス・インコーポレイテッドProMetic BioTherapeutics,Inc. プラミノーゲンを含む医薬組成物及びその使用
JP2018533589A (ja) * 2015-11-03 2018-11-15 プロメティック・バイオセラピューティクス・インコーポレイテッドProMetic BioTherapeutics,Inc. プラスミノーゲン欠損症のためのプラスミノーゲン補充療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020297A2 (en) * 2001-09-06 2003-03-13 Omnio Ab Method of improving wound healing
WO2009093970A1 (en) * 2008-01-22 2009-07-30 Omnio Healer Ab Method of improving wound healing
JP2018505209A (ja) * 2014-12-19 2018-02-22 プロメティック・バイオセラピューティクス・インコーポレイテッドProMetic BioTherapeutics,Inc. プラミノーゲンを含む医薬組成物及びその使用
JP2018533589A (ja) * 2015-11-03 2018-11-15 プロメティック・バイオセラピューティクス・インコーポレイテッドProMetic BioTherapeutics,Inc. プラスミノーゲン欠損症のためのプラスミノーゲン補充療法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD, 2012, VOL.119, NO.24, PP.5879-5887, JPN6020039778, ISSN: 0004517678 *

Also Published As

Publication number Publication date
WO2017081529A1 (en) 2017-05-18
MX2018005876A (es) 2018-11-09
EP3373957A1 (en) 2018-09-19
RU2018121234A3 (cg-RX-API-DMAC7.html) 2020-03-12
AU2016352183A1 (en) 2018-06-28
TW201722464A (zh) 2017-07-01
CN108289934A (zh) 2018-07-17
KR20180070708A (ko) 2018-06-26
US20180326023A1 (en) 2018-11-15
ZA201803010B (en) 2019-07-31
IL259172A (en) 2018-06-28
BR112018009476A8 (pt) 2019-02-26
RU2018121234A (ru) 2019-12-13
CA3004509A1 (en) 2017-05-18
BR112018009476A2 (pt) 2018-11-13

Similar Documents

Publication Publication Date Title
Rosyid Etiology, pathophysiology, diagnosis and management of diabetics’ foot ulcer
RU2711989C2 (ru) Фармацевтическая композиция, содержащая плазминоген, и ее применение
KR100795654B1 (ko) 당뇨성 발 절단 예방을 위한 표피성장인자 함유 약제학적조성물의 용도
US20180326023A1 (en) Plasminogen dosage regimen for wound healing
Lowe et al. Double-blind controlled clinical trial of ancrod for ischemic rest pain of the leg
Lai et al. The establishment and evaluation of a swine model of deinagkistrodon acutus snakebite envenomation
RU2734159C1 (ru) Фармацевтическая композиция для лечения болевого синдрома в стопе, включающая ботулинический токсин и гиалуроновую кислоту, и способ лечения болевого синдрома в стопе с ее использованием
US20040091506A1 (en) Topical antifungal treatment
Elkeles et al. ABC of vascular diseases. The diabetic foot
US10960011B2 (en) Compositions for the treatment of ischemic ulcers and stretch marks
US12521392B2 (en) Methods and compositions for promoting wound healing in a subject suffering from ectodermal dysplasias
Hon et al. Snakebite in a child: could we avoid the anaphylaxis or the fasciotomies?
Rahul et al. Hirudotherapy-a holistic natural healer: a review
Yoon et al. Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane.
Smart et al. Diabetic feet with plantar thermal burn wounds-a patient optimisation and preservative care approach
RU2539385C2 (ru) Способ лечения синдрома диабетической стопы
Katkar et al. Healingwith integrative management of Diabetic foot ulcer-A case report
Shepard The Impact of Diabetes Mellitus on Burns and Standard Burn Treatments
Pavlovich et al. Injecting material for skin regeneration Lacerta application in treatment of trophic ulcers in patients with diabetic foot syndrome
Ganatra et al. Integrative Management of a Post-debridement Non-healing Diabetic Foot Ulcer: A Case Report
Wynn et al. Case Report: Wound Care of a Diabetic Foot Ulcer.
RU2357735C1 (ru) Способ лечения критической ишемии нижних конечностей
BOLGARSKA et al. New Methods of Treatment for Trophic Lesions of the Lower Extremities in Patients with Diabetes Mellitus
Jalali et al. Treatment of a 41-year old female patient bitten by a viper conducted at the emergency department–A case report
Sriyani et al. An overview of diabetic foot ulcer disease at Colombo south teaching hospital: A preliminary study

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210601